Information Provided By: 
Fly News Breaks for March 6, 2018
BLRX
Mar 6, 2018 | 11:14 EDT
H.C. Wainwright analyst Joseph Pantginis noted that BioLineRx's Q4 and FY17 financial results missed the firm's estimates slightly, but he was optimistic about the company's second half data catalysts -- including topline results from COMBAT, lead-in stage results for the Phase 3 GENESIS study, partial results from Phase 1b/2 studies for BL-8040 in combination with Tecentriq in gastric cancer, NSCLC, and AML, as well as data from multiple other studies. Pantginis reiterated a Buy rating and has a $4 price target on BioLineRx shares.
News For BLRX From the Last 2 Days
There are no results for your query BLRX
